- Home
- DOCU vs SNN Comparison
DOCU vs SNN Comparison
Compare DOCU & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | SNN |
|---|---|---|
| Founded | 2003 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 12.3B |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DOCU | SNN |
|---|---|---|
| Price | $81.07 | $31.21 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 19 | 6 |
| Target Price | ★ $71.93 | $33.19 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 12-03-2026 | 08-04-2026 |
| Dividend Yield | N/A | ★ 2.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $3,219,500,000.00 | N/A |
| Revenue This Year | $8.86 | $3.93 |
| Revenue Next Year | $8.00 | $4.98 |
| P/E Ratio | $100.48 | ★ $64.97 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $40.16 | $26.30 |
| 52 Week High | $85.90 | $37.09 |
Technical Indicators
Market Signals| Indicator | DOCU | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 61.18 |
| Support Level | $42.89 | $31.21 |
| Resistance Level | $85.90 | $31.32 |
| Average True Range (ATR) | 2.71 | 0.58 |
| MACD | -0.58 | -0.03 |
| Stochastic Oscillator | 60.17 | 47.76 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.